Jonathan Young Sells 5,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $23.40, for a total value of $117,000.00. Following the transaction, the chief operating officer now directly owns 246,854 shares in the company, valued at $5,776,383.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, June 11th, Jonathan Young sold 2,516 shares of Akero Therapeutics stock. The stock was sold at an average price of $22.64, for a total value of $56,962.24.
• On Monday, June 3rd, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $19.29, for a total value of $96,450.00.
• On Wednesday, May 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $20.15, for a total value of $100,750.00.

Akero Therapeutics Stock Performance

NASDAQ:AKRO opened at $21.93 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 30.12 and a current ratio of 30.12. The stock has a market capitalization of $1.52 billion, a P/E ratio of -6.85 and a beta of -0.28. The company has a 50 day moving average price of $21.11 and a 200 day moving average price of $22.68. Akero Therapeutics, Inc. has a fifty-two week low of $11.25 and a fifty-two week high of $53.77.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.90) EPS for the quarter, meeting the consensus estimate of ($0.90). Equities research analysts forecast that Akero Therapeutics, Inc. will post -3.82 EPS for the current year.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Teachers Retirement System of The State of Kentucky boosted its position in Akero Therapeutics by 30.0% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 28,521 shares of the company’s stock valued at $720,000 after buying an additional 6,590 shares during the period. Virtu Financial LLC acquired a new stake in shares of Akero Therapeutics in the 1st quarter valued at $270,000. California State Teachers Retirement System raised its holdings in shares of Akero Therapeutics by 12.7% in the 1st quarter. California State Teachers Retirement System now owns 54,185 shares of the company’s stock valued at $1,369,000 after purchasing an additional 6,113 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after purchasing an additional 1,815,569 shares in the last quarter. Finally, Redmile Group LLC raised its holdings in shares of Akero Therapeutics by 67.5% in the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock valued at $46,951,000 after purchasing an additional 749,226 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on AKRO shares. Bank of America started coverage on Akero Therapeutics in a research report on Monday, April 22nd. They set a “neutral” rating and a $30.00 price target on the stock. Wolfe Research initiated coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. Evercore ISI dropped their price objective on shares of Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a report on Tuesday, June 11th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.13.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.